A Phase 1 interventional study of [14C] PF-07976016 and PF-07976016 in Healthy Male Volunteers, sponsored by Pfizer. Completed at 1 site in Netherlands. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-10.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
The purpose of this study is to learn about how much the study medicine PF-07976016 will be taken up and processed by healthy male participants. The total number of weeks of the study is up to approximately 12 weeks.
Pfizer is the lead sponsor of 3,244 studies on the registry; 139 are open to participants now.
Of its 582 completed or terminated interventional studies of FDA-regulated products, 381 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Participants will receive doses of PF-07976016 with and without radiolabel.
Drug: [14C] PF-07976016 · Drug: PF-07976016
\[14C\] PF-07976016 liquid (oral) formulation
PF-07976016 liquid (oral) formulation
\[14C\] PF-07976016 intravenous (IV) formulation
Total recovery of radioactivity expressed as a percent of total oral radioactive dose administered.
Time frame: From dose (Day 1) and for up to 21 days thereafter
Number of participants with treatment emergent adverse events
Time frame: First dose (Day 1) through 28 to 35 days after final dose (approximately 12 weeks)
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pfizer